Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528971 | 0.91 | DRD2 (0.44) | DRD2DRD3HTR2BSSTR4LTB4R | |
| Hydrochloric Acid SCHEMBL29960332 | 0.89 | DRD2 (0.43) | DRD2DRD3SSTR4LTB4RLTB4R2 | |
| Hydrochloric Acid SCHEMBL29960168 | 0.89 | DRD2 (0.43) | DRD2DRD3SSTR4LTB4RLTB4R2 | |
| SCHEMBL29960407 | 0.88 | DRD2 (0.43) | DRD2DRD3EEDHTR2BKDM1A | |
| Hydrochloric Acid SCHEMBL29960656 | 0.87 | DRD2 (0.42) | DRD2DRD3EEDHTR2BKDM1A | |
| SCHEMBL7847793 | 0.82 | DRD2 (0.48) | DRD2DRD3HTR2BSSTR4LTB4R | |
| SCHEMBL7846708 | 0.82 | DRD2 (0.48) | DRD2DRD3HTR2BSSTR4LTB4R | |
| SCHEMBL6245152 | 0.82 | DRD2 (0.48) | DRD2DRD3HTR2BSSTR4LTB4R | |
| SCHEMBL29960480 | 0.82 | DRD2 (0.48) | DRD2DRD3HTR2BSSTR4LTB4R | |
| SCHEMBL7846711 | 0.82 | DRD2 (0.48) | DRD2DRD3HTR2BSSTR4LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294487-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2024-09-05 | — | — | US | disclosed |
| US-11945789-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945789-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | XBP1, DDIT3, ERN1 | DRD2 4806/4885DRD3 4657/4885EED 3158/4885 |
| US-20240294487-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | XBP1, DDIT3, ERN1 | DRD2 4806/4885DRD3 4657/4885EED 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.